This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Hypogonadism; muscular atrophy	Androgen receptor	<p>A study in rats suggests that ACP-105, a nonsteroidal selective androgen receptor modulator (SARM), could help treat hypogonadism-associated conditions such as muscular atrophy and cachexia. In castrated rats, daily delivery of 0.1–3.0 mg/kg of ACP-105 via an osmotic minipump increased muscle growth compared with delivery of vehicle control. Next steps include preclinical safety studies. Acadia Pharmaceuticals Inc. is developing ACP-105, and the compound is in preclinical development for endocrine indications.</p> <p>At least six companies have SARMs in Phase II or earlier to treat musculoskeletal or endocrine diseases.</p> <p>SciBX 2(43); doi:10.1038/scibx.2009.1602 Published online Nov. 5, 2009</p>	Compound class is covered by multiple issued patents; available for licensing from Acadia Pharmaceuticals	<p>Schlienger, N. <i>et al. J. Med. Chem.</i>; published online Oct. 26, 2009; doi:10.1021/jm901149c</p> <p>Contact: Roger Olsson, Acadia Pharmaceuticals Inc., San Diego, Calif. e-mail: roger@acadia-pharm.com</p>